Lynparza approved in EU for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer
10 April 2019 07:00 BST Lynparza approved in EU for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer AstraZeneca and MSD's Lynparza reduced the risk of disease progression or death by 42% vs. chemotherapy in Phase III OlympiAD trial First PARP inhibitor approved in the EU for patients with this difficult-to-treat disease and third EU approval for Lynparza AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced the European Commission has approved Lynparza (olaparib) as a monotherapy for